Chidamide maintenance after PTCL first treatment
Treatments studied
Part of Cancer clinical trials.
This study looks back at people with PTCL who, after their initial first treatment, received chidamide as a continuing (maintenance) therapy. It aims to understand how effective and tolerated this approach may be in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with PTCL (peripheral T-cell lymphoma)
- After your first-line treatment, you received chidamide as maintenance therapy
- You do not have a different type of lymphoma
- You are not currently pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies chidamide (a prescription medicine) in people with diffuse large B-cell lymphoma that has come back or did not respond to at least one prior treatment. It may help shrink tumors and improve disease control for eligible patients.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
This trial tests a maintenance treatment called chidamide, which is a pill that may help prevent the cancer from coming back after a stem cell transplant. It is for people with a certain type of T-cell leukemia or lymphoma who have achieved complete remission after the transplant.
This trial tests a combination of two drugs, linperlisib and chidamide, for people whose peripheral T-cell lymphoma has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or control the lymphoma.
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.